NE PET PARTICIPATES IN ALZHEIMER’S FUNDRAISER

NE PET PARTICIPATES IN ALZHEIMER’S FUNDRAISER

Recently, two members of NE PET participated in the “Washburn Challenge”, an annual event held in Falmouth, MA to raise awareness of, and financial support for, Alzheimer’s Disease.

Our President & CEO Mark Taylor and Claire Coco Manager of our Accounting Department (pictured here with the Event’s Organizer Stuart McLeod), each completed the 22-mile Shining Sea Bike Path Ride, and Mark gave an update on the 2 Alzheimer’s Treatment Drugs now available for Alzheimer’s patients, and the critical role which New England PET plays in this new treatment process.

Currently, for the first time ever, there are 2 Drugs which have been approved by the FDA and CMS to treat Mild Cognitive Impairment and early Alzheimer’s Disease: Lequembi; which is made by Biogen & Esai, and Kisunla, which is made by Eli Lilly.

Prior to starting an Alzheimer’s patient on either one of these treatment drugs, CMS has required that the patient have a PET Scan, to prove that they have the Beta Amyloid Plaque in their brain, which these drugs are specially designed to treat, and which most clinicians believe is the cause of Alzheimer’s Disease.

All of NE PETS’s Scanning Sites are currently providing these Beta Amyloid PET Scans to Alzheimer’s patients.

Since its inception in 2017, The Washburn Challenge has raised over $1 Million for Alzheimer’s Research. In addition to the 22 mile Bike Ride, the event also includes a 7 mile Kayak Ride, food, live music, and incredible support for the Alzheimer’s Association.

NE PET plans to become a Sponsor of this important Event next year, and to have an entire Team participate in it.  

‍